Currently, the selection of patients with breast cancer for treatment with trastuzumab is based on the measurement of HER2 receptor protein expression by immunohistochemistry (IHC), or by the presence of HER2 gene amplification as detected by FISH. The gene discussed is ERBB2; the disease is breast carcinoma.